2024-03-28T08:21:11Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00000366
2022-12-14T04:01:51Z
30:31
Proteomics-based safety evaluation of multi-walled carbon nanotubes
Haniu, Hisao
Matsuda, Yoshikazu
Takeuchi, Kenji
Kim, Yoong Ahm
Hayashi, Takuya
Endo, Morinobu
Carbon nanotubes
Safety evaluation
Proteomics
Protein expression
In vitro
This study evaluated the biological responses to multi-walled carbon nanotubes (MWCNTs). Human monoblastic leukemia cells (U937) were exposed to As-grown MWCNTs and MWCNTs that were thermally treated at 1800 degrees C (HTT1800) and 2800 degrees C (HTT2800). Cell proliferation was highly inhibited by As-grown but not HTT2800. However, both As-grown and HTT1800, which include some impurities, were cytotoxic. Proteomics analysis of MWCNT-exposed cells revealed 37 protein spots on 2-dimensional electrophoresis gels that significantly changed (p<0.05) after exposure to HTT1800 with a little iron and 20 spots that changed after exposure to HTT2800. Peptide mass fingerprinting identified 45 proteins that included heat shock protein beta-1, neutral alpha-glucosidase AB, and DNA mismatch repair protein Msh2. These altered proteins play roles in metabolism, biosynthesis, response to stress, and cell differentiation. Although HTT2800 did not inhibit cell proliferation or cause cytotoxicity in vitro, some proteins related to the response to stress were changed. Moreover, DJ-1 protein, which is a biomarker of Parkinson's disease and is related to cancer, was identified after exposure to both MWCNTs. These results show that the cytotoxicity of MWCNTs depends on their impurities, such as iron, while MWCNTs themselves cause some biological responses directly and/or indirectly in vitro. Our proteomics-based approach for detecting biological responses to nanomaterials is a promising new method for detailed safety evaluations.
Article
Toxicology and Applied Pharmacology. 242(3):256-262 (2010)
journal article
ACADEMIC PRESS INC ELSEVIER SCIENCE
2010-02-01
application/pdf
Toxicology and Applied Pharmacology
3
242
256
262
0041-008X
AA00864435
https://soar-ir.repo.nii.ac.jp/record/366/files/Proteomics-Based_Safety_Evaluation.pdf
eng
19874835
https://pubmed.ncbi.nlm.nih.gov/19874835/
10.1016/j.taap.2009.10.015
https://doi.org/10.1016/j.taap.2009.10.015
Copyright © 2009 Elsevier Inc.